Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2019, Vol. 46 Issue (2): 195-200    DOI: 10.12891/ceog4423.2019
Original Research Previous articles | Next articles
Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?
Y. E. Purut1, E. E. Buyukbayrak2, F. Ercan1, *(), A. Orcun3, M. Menke3, A. Y. Karageyim Karsidag4
1Department of Obstetrics and Gynecology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya
2Department of Obstetrics and Gynaecology, Marmara University Pendik Education and Research Hospital, Istanbul
3Department of Biochemistry, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul ;
4Department of Obstetrics and Gynaecology, Kirklareli University, Kirklareli, Turkey
Download:  PDF(234KB)  ( 44 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Purpose of Investigation: The aim of this study is to evaluate whether first trimester maternal serum follistatin like 3 (FSTL3) levels can be used to predict preeclampsia and related obstetric complications. Materials and Methods: The serum levels of FSTL3, pregnancy associated plasma protein A (PAPP-A), and free β-hCG were determined in the first trimester from a sample of 180 pregnant women. All patients had first- and second-trimester ultrasound evaluations. The pregnancy outcome was defined as ‘adverse’ if one of the following outcomes were observed: fetal death, preeclampsia, pregnancy-induced hypertension (PIH), delivery of a small infant for gestational age (SGA) or preterm delivery. Results: FSTL3 levels were not significantly different for preeclampsia and related adverse obstetric outcomes compared to the control group (p < 0.05). Only PAPP-A MoM values were lower in the adverse obstetric outcome group than in the control (p = 0.040). There was no significant association among FSTL3 levels and the presence of any complications, according to our ROC curve analyses (p = 0.846). Conclusions: First trimester FSTL3 levels are not predictive for preeclampsia or adverse pregnancy outcomes.

Key words:  Adverse outcome      First trimester      Follistatin like 3      Preeclampsia      Pregnancy     
Published:  10 April 2019     
*Corresponding Author(s):  F. ERCAN     E-mail:  fediercan@gmail.com

Cite this article: 

Y. E. Purut, E. E. Buyukbayrak, F. Ercan, A. Orcun, M. Menke, A. Y. Karageyim Karsidag. Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 195-200.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4423.2019     OR     https://ceog.imrpress.com/EN/Y2019/V46/I2/195

[1] Amanda M. Wang, Alan J. Lee, Shannon M. Clark. The effects of overweight and obesity on pregnancy-related morbidity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 999-1009.
[2] Leen Van den Eeden, Greet Leysens,Dominique Mannaerts, Yves Jacquemyn. Air pollution: cardiovascular and other negative effects on pregnancy: a narrative review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1010-1016.
[3] Xin Du, Qian Zou, Yu-Lan Liu. Transumbilical single-hole laparoscopic treatment of cesarean scar pregnancy by uterine artery pre-ligation: a report of 4 cases[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1044-1047.
[4] Marcelo Epsztein Kanczuk, Nicholas J Lightfoot, Alison Pighills, Antony Ji, Casey Steele, Daniel Bartlett. The time to perform spinal or general anaesthesia in COVID-19 positive parturients requiring emergency caesarean delivery: a prospective crossover simulation study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1099-1106.
[5] Noor Hazim Abdulkareem, Elham Hazeim Abdulkareem. SARS-CoV-2 detection in pregnant and non-pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1141-1145.
[6] Min Jung Kim, Hee-Sook Lim, Hae-Hyeog Lee, Tae-Hee Kim, Yongsoon Park. Dietary assessment, nutrition knowledge, and pregnancy outcome in high-risk pregnant Korean women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1178-1185.
[7] Neha Sethi, Ann Gee Tan, Maherah Kamarudin, Sofiah Sulaiman. Successful delivery of a twin pregnancy with complete hydatidiform mole and coexistent live fetus: a case report and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1232-1247.
[8] Luca Roncati, Greta Gianotti, Elisa Ambrogi, Giovanna Attolini. COVID-19 in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 778-780.
[9] Silvia Amodeo, Giulia Bonavina, Anna Seidenari, Paolo Ivo Cavoretto, Antonio Farina. Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 812-819.
[10] Yu Deng, Zhan-Hui Ou, Min-Na Yin, Pei-Ling Liang, Zhi-Heng Chen, Abraham Morse, Ling Sun. Age and anti-Műllerian hormone: prediction of cumulative pregnancy outcome in in vitro fertilization with diminished ovarian reserve[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 835-841.
[11] Serdar Balci. The effect of ultraviolet index measurements on levels of vitamin D andinflammatory markers in pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 888-892.
[12] Anna M. Rubinshtein, Oleg V. Golyanovskiy. Obstetric outcomes in women of advanced maternal age after assisted reproduction[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 893-900.
[13] Qian Hu, Mohammed Sharooq Paramboor, Tao Guo. Diagnosis and management of intramural ectopic pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 974-979.
[14] Shingo Tanaka, Maki Goto, Saya Watanabe, Sachino Kira, Sotaro Hayashi, Shigeki Fujimoto, Miho Oda, Lifa Lee, Yoko To, Satoshi Nishiyama, Fuyuki Eguchi, Hiroshi Tsujioka. Posterior reversible encephalopathy syndrome with reversible cerebral vasoconstriction syndrome in a normal primigravida woman at the 35-week gestational stage: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 982-986.
[15] Ovadya Rosenbluh, Asnat Walfisch. Birth defects associated with obesity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 472-477.
No Suggested Reading articles found!